Morepen Laboratories Delivers Record Q2 & H1 FY27 Performance Driven by CDMO Scale-Up
Morepen Laboratories Ltd 路 Investor Presentation 路 27 Oct 2026, 7:13 pm
Morepen Laboratories Delivers Record Q2 & H1 FY27 Performance Driven by CDMO Scale-Up Morepen Laboratories reported strong Q2 FY27 results, with revenue surging 81% YoY to Rs. 755 Cr, EBITDA jumping 273% YoY to Rs. 132 Cr (margin up 897 bps to 17.45%), and PAT rising 117% YoY to Rs. 89 Cr. Growth was powered by CDMO revenues jumping 4.3x QoQ to Rs. 253 Cr, accounting for 52% of API + CDMO sales. For H1 FY27, revenue reached Rs. 1,330 Cr (+57% YoY) and PAT grew 177% YoY to Rs. 145 Cr, while TTM ROCE and ROE expanded to 18.8% and 13.6%.
Original exchange filing (PDF)
More announcements from Morepen Laboratories Ltd
- Update on Credit Rating 路 14 Nov 2026
- Please find attached the Press Release 路 09 Nov 2026
- Change in Senior Management Personnel on account of resignation 路 31 Oct 2026
- Change in Designation of Senior Management Personnel of the Company 路 28 Oct 2026
- Please find attached the monitoring agency report for the quarter ended September 30, 2026 路 27 Oct 2026
- Please find attached the press release 路 27 Oct 2026
- Please find attached the Q2 & H1 FY 27 Financial Results 路 27 Oct 2026
- Please find attached the Q2 & H1 FY27 Financial Results along with Limited Review Report 路 27 Oct 2026
